Elisabet E. Manasanch
0000-0002-0857-176X
12 papers found
Refreshing results…
Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis
Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis
Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms
The role of soluble B cell maturation antigen as a biomarker in multiple myeloma
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience
Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6
A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma
Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up
Gene expression profiling predicts relapse‐free and overall survival in newly diagnosed myeloma patients treated with novel therapies
Phase I/II study of high dose pomalidomide with G‐CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma
A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis
Missing publications? Search for publications with a matching author name.